Journal of Diabetes Research / 2015 / Article / Tab 1

Research Article

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Table 1

Baseline clinical characteristics.

Total patients
(n = 31)
Liraglutide
(n = 16)
Intensive insulin
(n = 15)
value

Age (years) 61.1 ± 10.5 62.3 ± 12.859.8 ± 7.7P = 0.53
Sex (male)71.0%81.3%60.0%P = 0.19
Body mass index (kg/m2)26.6 ± 2.727.3 ± 2.725.8 ± 2.5P = 0.12
Hypertension 77.4%75.0%80.0%P = 0.74
Dyslipidemia 58.1% 62.5%53.3%P = 0.61
Current smoking 19.4%12.5%26.7%P = 0.39
Duration of diabetes (years)11.1 ± 9.411.8 ± 9.210.3 ± 9.9P = 0.67
Family history of diabetes58.6%43.8%73.3%P = 0.15
Hemoglobin A1c (%)8.8 ± 1.08.7 ± 1.08.9 ± 0.9P = 0.66
Fasting plasma glucose (mg/dL)151.6 ± 31.7149.8 ± 33.3153.6 ± 30.9P = 0.74
Fasting blood insulin (µU/mL)8.5 (4.5–14.3)9.0 (4.8–17.0)5.2 (4.1–12.5)P = 0.17
Fasting blood CPR (ng/mL)2.2 ± 1.12.4 ± 1.22.0 ± 0.9P = 0.35
Antidiabetic medicines
 Sulfonylureas28.5% 25.0%26.0%P = 0.92
 Metformin12.9% 12.5%13.3%P = 1.00
 Alpha-glucosidase inhibitor6.5%6.3%6.7%P = 1.00
 DPP-4 inhibitor16.1%12.5%20.0%P = 0.65
 Insulin35.5%43.8%26.7%P = 0.46
Insulin use (units/day)29.7 ± 18.233.9 ± 20.623.8 ± 14.3P = 0.34

CPR: C-peptide radioimmunoreactivity; DPP-4: dipeptidyl peptidase.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.